Original Note. Certified true copy of the mortgage. 8. HUD-‐1.
Original Note. Executed Endorsement or Assignment of the Note.
Original Note. See the Recitals. Parent Companies. Collectively, Acme Holdings, Acme Intermediate, Acme Subsidiary Holdings, LLC, Acme Subsidiary Holdings II, LLC, Acme Intermediate Finance, Inc. and their controlled Affiliates from time to time.
Original Note. The “Note”, as defined in the Assignment of Loan Documents.
Original Note. This Note, together with Term Note A, supersedes and replaces that certain Term Note dated as of February 16, 2011 executed by Bank in favor of Maker in the amount of $10,000,000.
Original Note. A signed copy of the Note MUST be sent to Custody Operations-Privates for verification via fax 000-000-0000 or email XXXXxxxxxxXxxx@XXXXXXXX.xxx
Original Note. This Extension is amending a loan agreement that exists between the Parties for borrowed money equal to $[AMOUNT] that was given to the Borrower on [DATE] (“Original Note”).
Original Note. The unpaid balance of the Original Note is $8,626,007, as of the date hereof. The Original Note has been entered into in accordance with all applicable laws and there are no restrictions, governmental or otherwise, on the payment of the Original Note in accordance with its terms. The Seller has not pledged or assigned its rights under the Original Note, and on the Closing Date the Seller will have full right, power and authority to sell and assign to the Purchaser a forty-nine (49%) percent interest in and to the Original Note, free and clear of all security interests, liens and pledges. The Seller has delivered to the Purchaser a true and correct copy of the Original Note. 17.
Original Note. It is known that this Agreement is amending a note that exists between the Parties signed on (mm/dd/yyyy), for the sum of _ ___ Dollars ($ ) and maturing on _ (mm/dd/yyyy) (“Original Note”).
Original Note. This Note amends and restates the Senior Secured Convertible Promissory Note dated August 7, 2023, as amended, restated, replaced, supplemented or modified, made by the Company in favor of Israel Biotech Fund I, L.P. in an original principal amount of $2,000,000 (and thereafter partially assigned to Israel Biotech Fund II, L.P.) (the “Original Note”). This Note shall constitute a modification of the terms of the Original Note and evidences the same indebtedness that existed under the Original Note. To the extent that any rights, benefits or provisions in favor of Holder existed in the Original Note as of the date hereof, then such rights, benefits or provisions are acknowledged to be and to continue to be effective from and after the date of the Original Note. The Company and Holder agree and acknowledge that any and all rights, remedies and payment provisions under the Original Note, as hereby amended and restated, shall continue and survive the execution and delivery of this Note. The Company and Holder further agree and acknowledge that any and all amounts owing or otherwise due under or pursuant to the Original Note immediately prior to the effectiveness of this Note shall be owing and otherwise due pursuant to this Note. All references to the Original Note in any agreement, instrument or document executed or delivered in connection herewith or therewith shall be deemed to refer to this Note, as the same may be amended, restated, supplemented or otherwise modified from time to time.
